Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod PH20 SC for antibody-mediated rejection after kidney transplant
2023-508180-72-00Phase 2Authorised
- Sponsor
- argenx
- Start
- Dec 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in humoral rejection comparing Vyvgart PH20 SC with Placebo PH20 SC (2 arms). Primary endpoints: Incidence and severity of adverse events, Permanent treatment discontinuation due to adverse events and 1 more. Planned start Dec 2024; status: authorised.
02
Drugs
efgartigimod alfa
03
Conditions
humoral rejection
Beyond the preview
Go deeper on 2023-508180-72-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508180-72-00.